INTRODUCTION
B-cell chronic lymphocytic leukemia (B-CLL), one of the most common adult leukemias, is characterized by a highly heterogeneous clinical course. Some patients rapidly progress and die within a few months from diagnosis, whereas others live for several years with minimal or no treatment (1) . A comprehensive prognostic characterization of patients with B-CLL and identification of reliable prognostic markers is essential for tailoring therapeutic strategies (2) . Specific molecular alterations in gene expression and protein activity are thought to underlie the variability in disease outcome (3) (4) (5) . Among molecular indicators, the presence or absence of somatic mutations in the immunoglobulin heavy-chain variable gene (IgVH) appears to be the best prognostic discriminator, with the unmutated IgVH profile (<2% difference from germ-line) being associated with an aggressive clinical course (6, 7) . B-CLL is also characterized by a genomic instability that gives rise to several chromosomal aberrations, 11q, 13q, 17p deletions and 12 trisomy being the most relevant. While 11q and 17p deletions have been associated with rapid disease progression, the absence of chromosomal abnormalities or the presence of 13q deletion as the sole abnormality are associated with a better prognosis (8) (9) (10) . Despite the established prognostic value of these biomarkers, stratification based on these parameters failed to cover the complex heterogeneity of B-CLL.
Telomeres, which are specialized protective structures at the end of eukaryotic chromosomes, are progressively shortened during each round of cell replication because of end-replication problems of DNA polymerase (11) . The progressive shortening of telomeres is a key mechanism in controlling cellular replicative potential; when telomere erosion reaches a critical point, cells cease to proliferate and undergo senescence or apoptosis (12) . While maintenance of telomere length by telomerase is critical for preserving the replicative potential of cancer cells, further erosion of telomeres may impair their function in protecting chromosome ends, resulting in genetic instability, a key event in the initiation of carcinogenesis (13) (14) (15) . Recently, short telomeres have been associated with genetic complexity and short survival in B-CLL patients (16) (17) (18) .
Telomerase, a ribonucleoprotein complex containing an internal RNA template (hTR) and a catalytic protein with telomere-specific reverse transcriptase activity (hTERT), maintains telomere length by 4 adding hexameric TTAGGG repeats to the chromosomal ends, thus compensating for the continued replicative loss of telomeres (19) . hTERT is the rate-limiting component of the telomerase complex, and its expression correlates with telomerase activity (20, 21) . Telomerase activity, usually absent from normal somatic cells, is essential for unlimited cell growth and plays a critical role in tumorigenesis (22) . Several studies reported a relationship between levels of hTERT expression, telomerase activity and clinical aggressiveness of a variety of malignancies, including leukemia and lymphoma (23) (24) (25) . It has also been demonstrated that telomerase activity, or hTERT expression, may be a prognostic indicator of overall survival in B-CLL (26) (27) (28) . To date, only one study analyzed both telomere and telomerase in the same B-CLL patients, disclosing that unmutated IgVH had shorter telomeres and higher telomerase activity than mutated IgVH cases (29) . No study has yet analyzed both hTERT levels and telomere length in a large cohort of B-CLL, nor the interplay of hTERT expression/telomere length in relation to other known prognostic factors and disease outcome.
The aim of this study was to evaluate the interplay between hTERT expression and telomere length, 
DESIGN AND METHODS

Patients
Peripheral blood cells (PBL) were collected from 173 B-CLL patients (116 male and 57 female) who attended two institutions (Department of Clinical and Experimental Medicine, Hematology Section, Padova, and Department of Hematology, Vicenza). The median age was 62 (range 38 to 81) years. All samples were collected at the time of diagnosis, and all patients were untreated at the time of sampling.
Flow cytometry and fluorescence in situ hybridization (FISH) studies were performed on freshly collected peripheral blood samples, while IgVH mutational status, telomere length and hTERT levels were determined on paired frozen samples collected at the same time point. The median (interquartile) followup time from blood sampling was 45(31-73) months. The decision for primary treatment was taken 5 following general practice assessments (30) . Time from diagnosis to first treatment (TTFT) was considered as a marker for time to disease progression. Informed consent was obtained according to the Helsinki declaration and the study was approved by the local Ethics Committees.
IgVH mutation analysis and CD38 and ZAP-70 expression
IgVH gene status assessment was performed as previously described (28) . The cut-off of 2% mutations was employed to label unmutated (< 2%) and mutated (>2%) IgVH cases. Expression of CD38 and ZAP-70 proteins was performed by flow cytometry, as previously described (28) .
Fluorescence in Situ Hybridization
FISH was performed on standard cytogenetic preparations from peripheral blood. The slides were hybridized with the multicolour probe sets LSI p53/LSI ATM and LSI D13S319/LSI 13q34/ CEP12 (Vysis-Abbott, Des Plaines, IL, USA) according to the manufacturer's protocol. Three hundred interphase nuclei were analyzed for each probe. The cut-off for positive values (mean of normal control ±3 standard deviation) determined from 10 cytogenetically normal samples was 4% for centromere 12 trisomy (+12), and 10% for del 11q22.3(11q-), del13q14.3 (13q-) and del 17p13.1 (17p-). The B-CLL cases with 11q-or 17p-and 13q-(n=12) were included in the group of 11q-,17p-.
Determination of telomere length and quantification of hTERT transcripts
Telomere length was determined by real-time PCR, exactly as previously described (31) , and values were expressed as telomere/single copy-gene (T/S) ratio. The conversion of T/S values to Kb was performed according to the adjusted formula y=1.53x+3.62 (31) . Quantification of all hTERT transcripts in B-CLL samples was carried out by real-time PCR using the AT1 and AT2 primer pair, exactly as previously described (28) ,and hTERT values were normalised for 10 6 copies of the housekeeping gene GAPDH (28) .
Quantification of telomerase activity by real-time PCR
Two million cells were lysed in 50-60 µL of CHAPS buffer (0.5% CHAPS, 10 mM Tris HCl, pH 7.5, 1 mM MgCl 2 , 1 mM EGTA, 0.1 mM phenylmethyl-sulfonyl fluoride, 5 mM β -mercaptoethanol, and 10% 6 glycerol) and incubated at 4 °C for 30 min. The lysate was then centrifuged at 12000 g for 30 min at 4 °C, and the supernatant was collected as previously reported (26) . The protein concentration was measured using NanoDrop spectrophotometry (ND-1000; Celbio). Telomerase activity was evaluated by real-time PCR method (32), using 250 ng of cellular protein extract for each sample. Threshold cycle values (Ct) of the samples were plotted against a standard curve generated from serial five-fold dilutions starting from 2 µg protein extract from telomerase-positive BL41 cells. Each sample was analyzed in duplicate and values were expressed as relative units.
Statistical analyses
The distribution of continuous variables, such as hTERT levels, telomere length and age, were compared by the Kruskal-Wallis test and the associations among nominal variables were analyzed by χ 2 test. For each variable, TTFT analysis was performed using the Kaplan-Meier method and compared by the logrank test. hTERT levels and telomere length were analyzed as dichotomous variables (cut-off: ≤ median or >median). Hazard ratios for each category were estimated using univariate Cox proportional hazards models with low risk as the reference class. TTFT analysis was also performed to explore the interplay of hTERT and telomere length, with inclusion of the interaction term. The independent role of hTERT/telomere interplay in predicting TTFT was tested using the Cox proportional hazards model adjusting separately for cytogenetic categories and IgVH mutational status. This choice was due to the dataset reduction driven by the fact that not all subjects had both FISH and IgVH mutational data. The proportionality assumption was tested by including time-dependent covariates in each model. All tests were two-sided, and a p<0.05 was considered statistically significant. Statistical analyses were performed using the SAS version 9.1 (SAS Institute, Cary, NC).
RESULTS hTERT expression and telomere length in B-CLL cases
The median (interquartile, IQR) hTERT level, determined in 151 B-CLL samples, was 106 copies/10*6 GAPDH ( Figure 1A ). In agreement with a previous observation (28) , levels of hTERT 7 mRNA significantly correlated with telomerase activity (r s =0.546, p=0.011) ( Figure 1B hTERT expression and telomere length in relation to genomic aberrations FISH analysis was performed in 125 cases; 19% had 11q-or 17p-, 34% had the 13q-as the sole chromosomal aberration, 10% were +12, and 37% of the cases had no chromosomal abnormalities and were considered as normal. hTERT levels were significantly higher in B-CLL with 11q-or 17p Figure 3D and Table 2 Supplement).
Distribution of hTERT level and telomere length in the B-CLL subsets defined by IgVH mutational status and chromosomal aberrations
hTERT was defined as high or low, and telomere as long or short according to their values above and below the median, respectively. High hTERT levels and short telomeres were more frequent in unmutated than mutated IgVH B-CLL cases ( Figure 4A ). Chromosomal aberrations 11q-, 17p-or +12 were more frequent in high than low hTERT and in short than long telomere B-CLL cases ( Figure 4C ).
Most of the B-CLL with low hTERT levels had long telomeres (66%), while the majority of the B-CLL with high hTERT levels had short telomeres (67%) (p=0.0001). Thus, two prevalent groups of B-CLL 9
were identified: one with high hTERT level/short telomere (33%) and one with low hTERT level/long telomere (34%). Fewer cases had high hTERT level/long telomere (17%) or low hTERT level/short telomere (16%). The B-CLL cases with high hTERT/short telomere were characterized by unmutated IgVH status (73%) ( Figure 4B ), and chromosomal abnormalities (74%) ( Figure 4D) . Notably, the most frequent genomic aberrations in B-CLL with high hTERT/short telomere were 11q-, 17p-, or +12 (57%), while 40% of low hTERT/long telomere and 65% of low hTERT/short telomere B-CLL had the 13q-( Figure 4D ). Figure 6A , and Table 3 Supplement). B-CLL patients with low hTERT levels or long telomeres and a mutated IgVH profile showed a significantly better prognosis than patients with high hTERT levels or short telomeres and unmutated IgVH ( Figure 1A , 1B Supplement, and Table 4 Supplement). Multivariate analyses confirmed the independent value of hTERT/telomere interplay in relation to IgVH mutational status. High hTERT/short telomere and low hTERT/long telomere profiles discriminate two subgroups of B-CLL with different clinical outcomes within both the IgVH mutated and unmutated cases. This is of particular relevance in the mutated IgVH cases; patients with high hTERT/short telomere B-CLL had a poor prognosis with a median TTFT of 49 (4;108) months, significantly shorter than those shared by B-CLL cases with a low hTERT/long telomere profile ( Figure 6B , and Table 4 Supplement).
Concerning chromosomal categories, 11q-or 17p-B-CLL had the worst clinical outcome, while 13q-B-CLL had the best prognosis [median (95%CI) 3(2-13) months vs -(77;-) months]; p<0.0001] ( Table 3 Supplement). Median TTFT of 13q-cases did not significantly differ from that of normal B-CLL; thus, B-CLL with these two chromosomal profiles had a significantly longer disease-free interval than those having 11q-, 17p-or +12 abnormalities ( Figure 6C , and Table 3 Supplement). Stratification of patients according to hTERT level or telomere length and chromosomal profile disclosed that B-CLL cases with high hTERT levels or short telomeres and high-risk abnormalities (i.e. 11q-, 17p-, +12) had a poorer prognosis than cases with low hTERT or long telomeres and a low-risk genomic profile (i.e. normal or 13q-) ( Figure 1C , 1D Supplement, and Table 5 Supplement). Multivariate analyses confirmed the independent value of hTERT/telomere interplay in relation to chromosomal status. High hTERT/short telomere profile identified subgroups of patients with the poorest clinical outcome; this is of particular relevance in the B-CLL cases with no or low-risk abnormalities. Within this group, B-CLL with high hTERT/short telomere had a significantly more rapid disease progression than those with low hTERT/long telomere ( Figure 6D , and Table 5 Supplement).
Due to sample number, the independent role of hTERT/telomere interplay in predicting TTFT was tested separately for IgVH mutational status and chromosomal categories. However, stratification of cases analyzed for tested risk factors, disclosed that B-CLL patients characterized by unmutated IgVH status, 11q-,17p-, or +12 chromosomal abnormalities, high hTERT /short telomere developed the disease (17/18) within a median (95%) time of 2(1;16)months; in contrast, none of the 22 patients with any of the above risk factors progressed clinically within a median follow-up period of 42 months ( Figure 6F ).
DISCUSSION
This study analyzed for the first time both hTERT levels and telomere length and their relationship with
IgVH mutational status and chromosomal aberrations in a large cohort of B-CLL patients. Although the main function of hTERT is to stabilize telomere length (12, 20, 21, 34) , an inverse relationship between hTERT levels and telomere lengths was found in B-CLL cases. Notably, B-CLL cases with high telomerase levels and short telomeres were frequently characterized by an unmutated IgVH status and high-risk chromosomal aberrations. Conversely, B-CLL cases with low telomerase levels and long telomeres were associated with a mutated IgVH status and low-risk abnormalities.
All together these findings may have important implications on the pathogenesis of B-CLL. During Tcell-mediated germinal center (GC) experience, B cells activate telomerase and exhibit telomere lengthening (35, 36) . Somatic hypermutation of Ig genes is a physiological process occurring in the GC;
thus, B-CLL cases with unmutated IgVH genes are likely originated from pre-GC B lymphocytes and those with mutated IgVH genes from GC-experienced B lymphocytes. Our data show that mutated IgVH
GC-experienced B-CLL had longer telomeres than the unmutated IgVH B-CLL, in agreement with
previous results (16, 29, 33, 37) . Of interest, the unmutated IgVH B-CLL cases with short telomeres had higher levels of hTERT than the mutated IgVH cases with long telomeres. This finding highlights the concept that telomere length in tumours, rather than being associated with hTERT levels, reflects the initial kinetics of telomere erosion by cell proliferation (13, 38, 39) . Our finding that short telomeres are associated with chromosomal abnormalities supports the concept that erosion of telomeres may impair their function in protecting chromosome ends, resulting in genetic instability (13, 15) and reinforces the concept that activation of hTERT is subsequent to telomere shortening, particularly in a subgroup of B-CLL cases (40) . This finding is consistent with recent evidence of short telomeres in a subset of earlystage patients (18) . Our results also demonstrated that B-CLL with the highest proliferative index (i.e.
lymphocyte doubling time <6 months) had the shorter telomere length, a finding that supports the notion of telomere shortening at each cell division cycle. Thus, in B-CLL with short telomeres, high hTERT levels are essential to maintaining the replicative potential of tumor cells. Conversely, the pre-existing 12 activation of telomerase in GC-experienced B lymphocytes may explain the long telomere in mutated IgVH B-CLL cases, despite the low levels of hTERT.
While high-risk chromosomal aberrations were more frequent in B-CLL with short telomeres and high hTERT levels, the distribution of the 13q deletion was intriguing. It was also detected in B-CLL with long telomeres, and was predominant in B-CLL cases with low hTERT levels. Most of the 13q-B-CLL had stable lymphocyte doubling time; this slow kinetics of cellular division may require low levels of hTERT to preserve the replicative potential. MicroRNA 15 and 16 are localized in 13q14 (41), but molecular aberrations underlying the 13q deletion are not fully characterized (42) . How the 13q deletion impacts the cell cycle and levels of hTERT remains a very interesting question to be addressed.
In agreement with previous studies, we found that unmutated IgVH status (6,7), 11q-or 17p-and +12
aberrations (8) (9) (10) , high levels of hTERT (26) (27) (28) , and low telomere length (16, 17, 29, 33) were all associated with a poor clinical outcome. Finding that the 13q-, characterized by low levels of hTERT, was associated with a prognosis even better than the normal group, supports the notion that hTERT may contribute to lymphomagenesis beyond just preservation of telomere length (43) (44) (45) . In addition, the study of all these biomarkers in the same B-CLL cohort allowed us to identify new potential risk profiles. The poorest prognosis was found in the group with high hTERT levels and low telomere lengths, whereas B-CLL with low hTERT levels and long telomere length had a more indolent clinical behaviour. It should be stressed that even within the group of B-CLL patients with unmutated IgvH and/or high risk chromosomal aberrations that had the poorest clinical outcome (46), those with low levels of hTERT and long telomeres had a better outcome. Most importantly, the evaluation of hTERT and telomere length might help the clinician in the management of B-CLL patients with mutated IgVH and/or no high-risk chromosomal aberrations since cases with high hTERT/short telomere B-CLL will progress more rapidly and might require therapy earlier than those with low hTERT/long telomeres.
In conclusion, our data demonstrated for the first time that the combined parameter telomere/telomerase is a strong predictor of progression in B-CLL patients. This is important for deepening the knowledge of the pathogenesis of B-CLL as well as for the management of disease and the development of new therapeutic strategies. Table 1 and 2, Supplement section. Table 3 , Supplement section. Tables 3 (panel A, 
